Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

5(100.0%)

5Total

Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00639639Phase 1Completed

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Role: lead

NCT03283631Phase 1Terminated

Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM

Role: lead

NCT00626483Phase 1Completed

Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia

Role: lead

NCT03615404Phase 1Completed

Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma

Role: lead

NCT02529072Phase 1Completed

Nivolumab With DC Vaccines for Recurrent Brain Tumors

Role: lead

All 5 trials loaded